A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors



Status:Recruiting
Conditions:Lung Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:August 15, 2018
End Date:November 7, 2022
Contact:Pfizer CT.gov Call Center
Email:ClinicalTrials.gov_Inquiries@pfizer.com
Phone:1-800-718-1021

Use our guide to learn which trials are right for you!

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB IN COMBINATION WITH BINIMETINIB WITH OR WITHOUT TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RAS-MUTANT SOLID TUMORS

This Phase 1b/2 study will examine the effects of the study drugs, avelumab and binimetinib
given together (doublet) and in combination with talazoparib (triplet), in patients with
locally advanced or metastatic RAS-mutant solid tumors. The Phase 1b part of the study will
assess if the different study drugs can be given together safely and which doses to use for
further research. Phase 2 will test if the study treatments have an effect on tumor size and
growth, and gather more information about potential side effects.

This is a Phase 1b/2, open label, multi-center, safety, clinical activity, pharmacokinetic
(PK), and pharmacodynamics (PD) study of avelumab in combination with binimetinib with or
without talazoparib in adult patients with locally advanced or metastatic KRAS- or
NRAS-mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma, or other KRAS- or
NRAS-mutant solid tumors.

The Phase 1b part of this study will initially assess the combination of avelumab and
binimetinib (doublet) to determine a recommended dose for further investigation. Following
this, the recommended dose for the combination of avelumab, binimetinib and talazoparib
(triplet) will be determined. The recommended doses for the doublet and triplet combinations
will be used in the Phase 2 part of the study, which will assess the safety and preliminary
anti-tumor activity of the study treatments.

Inclusion Criteria:

- Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid
tumors that are not amenable for treatment with curative intent as follows:

1. Stage IIIb/IV NSCLC with documented positive KRAS or NRAS mutation status as
determined using a validated test performed in a College of American Pathologists
(CAP)/Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (or
other comparable local or regional certification); or

2. Metastatic pancreatic ductal adenocarcinoma; or

3. Phase 2 only: other advanced solid tumors with documented positive KRAS or NRAS
mutation as determined using a validated test performed in a CAP/CLIA-certified
laboratory (or other comparable local or regional certification).

- Have had disease progression during or following at least 1 and not more than 2 prior
lines of treatment for advanced or metastatic disease.

- Patients with NSCLC must have previously received treatment with an anti-PD-1 or
anti-PD-L1 agent for advanced disease.

- Measurable disease as per RECIST v1.1 criteria.

- Provision of a baseline tumor sample.

- Age ≥18 years (Japanese patients must be ≥20 years old)

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.

- Adequate bone marrow, renal and liver functions.

- Adequate cardiac function.

- Informed consent provided.

Exclusion Criteria:

- Prior treatment with avelumab, a PARP inhibitor or MEK inhibitor.

- Prior systemic anti-cancer therapy within 2 weeks prior to study enrollment.

- Persisting toxicity related to prior therapy.

- Current use of immunosuppressive medication.

- Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis,
pulmonary fibrosis, uveitis or iritis.

- Active or prior autoimmune disease that might deteriorate when receiving an
immunostimulatory agent.

- Diagnosis of myelodysplastic syndrome (MDS).

- Known symptomatic brain metastases requiring steroids.

- Known history of testing positive for HIV or hepatitis.

- Clinically significant (ie, active) cardiovascular disease.

- History of thromboembolic or cerebrovascular events.

- Current or anticipated use of a P-gp inhibitor, inducer, or inhibitor of breast cancer
resistance protein (BCRP)

- Uncontrolled hypertension.

- Concurrent neuromuscular disorder that is associated with the potential of elevated
creatinine kinase.

- Known history of Gilbert's syndrome.

- History or current evidence of retinal degenerative disease, retinal vein occlusion
(RVO) or current risk factors for RVO.

- Other acute or chronic medical or psychiatric condition.
We found this trial at
13
sites
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Brussels,
Click here to add this to my saved trials
?
mi
from
Encinitas, CA
Click here to add this to my saved trials
Fayetteville, Arkansas 72703
?
mi
from
Fayetteville, AR
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lafayette, Indiana
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rogers, Arkansas 72758
?
mi
from
Rogers, AR
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
San Marcos, CA
Click here to add this to my saved trials